Author:
Ko H-J,Kim Y-J,Kim Y-S,Kim J-M,Ho S-H,Jeong J-G,Oh S-M,Chae J-A,Kim C-Y,Lee P-S,Kang C-Y
Publisher
Springer Science and Business Media LLC
Subject
Genetics,Molecular Biology,Molecular Medicine
Reference42 articles.
1. Gullick WJ, Love SB, Wright C, Barnes DM, Gusterson B, Harris AL et al. c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer 1991; 63: 434–438.
2. Disis ML, Calenoff E, McLaughlin G, Murphy AE, Chen W, Groner B et al. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 1994; 54: 16–20.
3. Brossart P, Stuhler G, Flad T, Stevanovic S, Rammensee HG, Kanz L et al. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res 1998; 58: 732–736.
4. Chang SY, Lee KC, Ko SY, Ko HJ, Kang CY . Enhanced efficacy of DNA vaccination against Her-2/neu tumor antigen by genetic adjuvants. Int J Cancer 2004; 111: 86–95.
5. Chung Y, Kim BS, Kim YJ, Ko HJ, Ko SY, Kim DH et al. CD1d-restricted T cells license B cells to generate long-lasting cytotoxic antitumor immunity in vivo. Cancer Res 2006; 66: 6843–6850.
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献